Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Justin Yan

Otolaryngology Arvada, CO Medical Doctor

NPI 1184990962 CMS profile 3421728

7850 Vance Dr Ste 225, Ste 225, Arvada, CO 80003

Open in the dashboard

General payments

$3,816

13 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Justin Yan of Arvada, CO is reported in the CMS Open Payments database as having received $3,816 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,438 5
2021 General $896 2
2020 General $1,368 4
2019 General $115 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Yan
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Justin Yan were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Justin Yan Otolaryngology median Middle half National median
2019 $115 $194 $82–$512 $163
2020 $1,368 $118 $42–$280 $114
2021 $896 $167 $63–$444 $132
2022 $1,438 $216 $84–$545 $149
2023 $0 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Medtronic, Inc. $2,206 4 payments
  2. Medtronic USA, Inc. $1,293 2 payments
  3. Integra LifeSciences Corporation $100 1 payment
  4. Intersect ENT, Inc. $96 1 payment
  5. Stryker Corporation $69 2 payments
  6. Acclarent, Inc $25 1 payment
  7. Regeneron Healthcare Solutions, Inc. $15 1 payment
  8. GlaxoSmithKline, LLC. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $3,480 3 payments
  2. Food and Beverage $336 10 payments
Products named General payments · program years 2019–2022
  1. STEALTHSTATION S8 PLATFORM $1,406 3 payments
  2. FUSION Image Guided Surgery Products $1,293 2 payments
  3. FUSION Image Guided Surgery Products $800 1 payment
  4. AMNIOEXCEL $100 1 payment
  5. BILAYER WOUND MATRIX (BWM) $100 1 payment
  6. INTEGRA WOUND MATRIX (IWM) $100 1 payment
  7. IDRT $100 1 payment
  8. FLOWABLE $100 1 payment
  9. PROPEL $96 1 payment
  10. ENTELLUS - XPRESS OFFICE START-UP KITS $50 1 payment
  11. Other $72 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

607

Median for Otolaryngology: 297

Drug cost

$21,056

Median for Otolaryngology: $6,314

Branded share of claims

21.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 114 $11,052
Azelastine Hcl Generic 85 $2,927
Fluticasone Propionate Generic 176 $2,834
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 13 $1,728
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 70 $802
Ipratropium Bromide Generic 23 $732
Methylprednisolone Generic 41 $300
Ofloxacin Generic 12 $238
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 33 $165
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $118

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$87,498

Medicare's payments for the services billed

Medicare patients

323

Average age 74

Services billed

1,000

188 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 49%
Ischemic heart disease 23%
Depression 23%
Chronic kidney disease 22%
Diabetes 21%
Atrial fibrillation 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record